Quest Diagnostics will report results on October 22 for Quest Diagnostics stock

Published on 10/17/2026 at 21:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue hit USD 3.04 billion. Quest Diagnostics stock stood at EUR 212.00 on October 16, 2026, up 2.37 percent versus the Frankfurt close.

Results date and valuation

Quest Diagnostics will report third-quarter results before the market opens on October 22, 2026.
Second-quarter revenue reached USD 3.04 billion and rose 10.20 percent year over year.
Quest Diagnostics stock stood at EUR 212.00 in Frankfurt on October 16, 2026, 2.37 percent above the Frankfurt close of October 15, 2026.
Quest Diagnostics carried a P/E ratio of 24.95 and a market capitalization of USD 25.9 billion as of October 16, 2026.

Automatisierter Laboranalysator mit Blutproben-Röhrchen in klinischem Diagnostiklabor — Quest Diagnostics US74834L1008 zeigt automatisierten Laboranalysator mit Blutproben in modernem Diagnostiklabor fotorealistisch dargestellt, Illustration mit AI erstellt.

Quest Diagnostics (ISIN US74834L1008) will report its third-quarter 2026 results before the market opens on October 22, 2026, according to Quest Diagnostics. The date gives the next clear checkpoint for the laboratory testing company. The Frankfurt quote last stood at EUR 212.00 on October 16, 2026 at 8:00 a.m. CEST, up 2.37 percent versus the Frankfurt close of October 15, 2026 (EUR 207.10).

Revenue grew 10.20 percent

Quest Diagnostics entered the reporting date with a stronger second-quarter operating base. Revenue reached USD 3.04 billion in the second quarter of 2026, an increase of 10.20 percent from the year-earlier period, while adjusted earnings per share came to USD 3.12 versus USD 2.82 consensus. MarketBeat reported the comparison on October 15, 2026.

Stock range and yearly high

On the NYSE, Quest Diagnostics was last at USD 235.00 on October 16, 2026 at 4:00 p.m. ET. Its 52-week range was USD 171.18 to USD 248.84, putting the latest US quotation 5.56 percent below the yearly high. Trading volume was 799,642 shares against an average of 1,050,817 shares.

Valuation and October 22 date

Quest Diagnostics had a market capitalization of USD 25.9 billion and a P/E ratio of 24.95 as of October 16, 2026. Its quarterly dividend was USD 0.86 per share, with payment scheduled for October 21, 2026, according to MarketBeat. The company said in its September 22, 2026 release that third-quarter results would be published on October 22, 2026 before the US market opens, as Quest Diagnostics announced.

Comparison with peers

Quest Diagnostics (NYSE, USD): plus 2.37 percent, P/E 24.95, market capitalization USD 25.9 billion
Labcorp (NYSE, USD): minus 2.19 percent, P/E 26.30, market capitalization USD 25.8 billion
DaVita (NYSE, USD): minus 0.98 percent, P/E 16.46, market capitalization USD 12.0 billion

Frankfurt quote sets the frame

The German quote sits below the US 52-week high while the next scheduled report is less than a week away. The Frankfurt quote last stood at EUR 212.00 on October 16, 2026 at 8:00 a.m. CEST, 2.37 percent above the Frankfurt close of October 15, 2026 (EUR 207.10).